The oral dual endothelin receptor antagonist bosentan has been shown to improve the short- and medium-term course of adult pulmonary arterial hypertension (PAH); however, data from clinical studies in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback